Psoriatic ArthritisPhase 3NCT04908202
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
A Phase 3 study testing Deucravacitinib in people with Psoriatic Arthritis, run by Bristol-Myers Squibb at 183 sites in 21 countries.
Trial summary
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Psoriatic Arthritis
- What is being tested?
- Deucravacitinib
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 670 participants
- Where
- 183 sitesin 21 countries
- Study dates
- 13 Jul 2021to 3 Jun 2027
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at screening.
- Meets the Classification Criteria for Psoriatic Arthritis at Screening.
- Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at screening.
- Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and day 1.
- Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening.
- ≥ 1 PsA-related hand and/or foot joint erosion on X-ray during Screening Period that is confirmed by central reading.
- Must have completed the week 52 treatment for the optional open-label long-term extension period.
Who cannot join
- Nonplaque psoriasis at screening or day 1.
- Other autoimmune condition such as systemic lupus erythematous, mixed connective tissue disease, multiple sclerosis, or vasculitis.
- History of or current inflammatory joint disease other than PsA (e.g., gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease).
- Active fibromyalgia.
- Received an approved or investigational biologic therapy for the treatment of PsA or PsO.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Trial locations and contacts
183 sites in 21 countries.
183 sites in 21 countries
United States33 sites
Local Institution - 0172
Allen, Texas, 75013
Local Institution - 0189
Amarillo, Texas, 79124
Local Institution - 0181
Beckley, West Virginia, 25801
Local Institution - 0087
Boise, Idaho, 83702
Local Institution - 0273
Bothell, Washington, 98021
Local Institution - 0080
Chicago, Illinois, 60640
Local Institution - 0195
Clearwater, Florida, 33765
University Hospitals Cleveland Medical Center-Dermatology
Cleveland, Ohio, 44106
Local Institution - 0185
Corvallis, Oregon, 97330
Local Institution - 0032
Dallas, Texas, 75231
Local Institution - 0170
Denver, Colorado, 80230
Local Institution - 0198
Detroit, Michigan, 48202
Local Institution - 0168
Fontana, California, 92335
Local Institution - 0199
Fullerton, California, 92835
Local Institution - 0171
Gainesville, Georgia, 30501
Local Institution - 0197
Gilbert, Arizona, 85297
Local Institution - 0175
Greenville, South Carolina, 29601
Local Institution - 0042
Hagerstown, Maryland, 21740
Local Institution - 0036
Jackson, Tennessee, 38305
Local Institution - 0188
Jonesboro, Arkansas, 72401
Local Institution - 0268
Kalispell, Montana, 59901
Local Institution - 0083
Lexington, Kentucky, 40504
Local Institution - 0272
Margate, Florida, 33063
Local Institution - 0082
Miami Lakes, Florida, 33014
Local Institution - 0028
Middleburg Heights, Ohio, 44130
Local Institution - 0182
Oklahoma City, Oklahoma, 73102
Local Institution - 0177
Orland Park, Illinois, 60467
Local Institution - 0179
Perrysburg, Ohio, 43551
Local Institution - 0038
Sacramento, California, 95815
Local Institution - 0178
Schaumburg, Illinois, 60195
Local Institution - 0201
Springfield, Missouri, 65807
Cohen Medical Centers
Thousand Oaks, California, 91360
Local Institution - 0186
Voorhees Township, New Jersey, 08043
Poland27 sites
Local Institution - 0114
Bialystok, 15-351
Local Institution - 0241
Częstochowa, Silesian Voivodeship, 42-202
Local Institution - 0231
Dąbrówka, Greater Poland Voivodeship, 62-069
Local Institution - 0257
Gdansk, Pomeranian Voivodeship, 80-382
Local Institution - 0234
Gdynia, Pomeranian Voivodeship, 31-338
Local Institution - 0252
Katowice, Silesian Voivodeship, 40-040
Local Institution - 0229
Krakow, Lesser Poland Voivodeship, 30-149
Local Institution - 0126
Krakow, 30-002
Local Institution - 0127
Krakow, 30-033
Local Institution - 0140
Krakow, 31-501
Local Institution - 0238
Lodz, Łódź Voivodeship, 90-368
Local Institution - 0232
Lublin, Lublin Voivodeship, 20-607
Local Institution - 0233
Nadarzyn, Masovian Voivodeship, 05-830
Local Institution - 0206
Nowy Targ, Lesser Poland Voivodeship, 34-400
Local Institution - 0162
Olsztyn, 10-117
Local Institution - 0113
Poznan, 60-218
Local Institution - 0239
Poznan, 60-702
Local Institution - 0112
Poznan, 60-773
Local Institution - 0230
Świdnik, Lublin Voivodeship, 21-040
Local Institution - 0235
Warsaw, Masovian Voivodeship, 02-665
Local Institution - 0243
Warsaw, Masovian Voivodeship, 02-672
Local Institution - 0204
Warsaw, 00-874
Local Institution - 0205
Warsaw, 02-118
Local Institution - 0125
Warsaw, 03-291
Local Institution - 0236
Wołomin, Masovian Voivodeship, 05-200
Local Institution - 0244
Wroclaw, Lower Silesian Voivodeship, 50-381
Local Institution - 0210
Wroclaw, 52-210
Romania14 sites
Local Institution - 0012
Brasov, 500283
Local Institution - 0090
Bucharest, Bucharest, 011172
Local Institution - 0266
Bucharest, Bucharest, 020125
Local Institution - 0167
Bucharest, 011025
Local Institution - 0260
Bucharest, 014142
Local Institution - 0263
Bucharest, 030463
Local Institution - 0184
Bucharest, 11057
Local Institution - 0011
Cluj-Napoca, 400006
Local Institution - 0258
Craiova, 200347
Local Institution - 0262
Iași, 700127
Local Institution - 0265
Iași, 700661
Local Institution - 0264
Iași, 700714
Local Institution - 0010
Râmnicu Vâlcea, Vâlcea County, 247065
Local Institution - 0091
Timișoara, 300778
Argentina10 sites
Local Institution - 0194
Buenos Aires, 1426
Local Institution - 0169
Buenos Aires, 1428
Local Institution - 0192
Buenos Aires, C1427CCL
Local Institution - 0213
Ciudad Autónoma de Buenos Aires, Buenos Aires, 1111
Local Institution - 0046
Córdoba, Córdoba Province, X5004CDT
Local Institution - 0054
La Plata, Buenos Aires, 1900
Local Institution - 0193
Mendoza, 5500
Local Institution - 0215
Quilmes, Buenos Aires, 1878
Local Institution - 0196
Rosario, Santa Fe Province, S2000
Local Institution - 0047
San Miguel de Tucumán, Tucumán Province, 4000
Bulgaria10 sites
Local Institution - 0253
Burgas, 8000
Local Institution - 0255
Plovdiv, Plovdiv, 4002
Local Institution - 0249
Plovdiv, 4000
Local Institution - 0267
Plovdiv, 4000
Local Institution - 0246
Plovdiv, 4001
Local Institution - 0247
Plovdiv, 4001
Local Institution - 0248
Sofia, Sofia (stolitsa), 1463
Local Institution - 0245
Sofia, 1505
Local Institution - 0259
Sofia, 1784
Local Institution - 0250
Varna, 9000
Mexico9 sites
Local Institution - 0060
Chihuahua City, 31000
Local Institution - 0254
Guadalajara, Jalisco, 44610
Local Institution - 0061
Mérida, Yucatán, 97070
Local Institution - 0212
Mérida, Yucatán, 97070
Local Institution - 0057
Mexico City, Mexico City, 06720
Local Institution - 0209
Mexico City, 14080
Local Institution - 0056
Saltillo, Coahuila, 25050
Local Institution - 0128
San Luis Potosí City, San Luis Potosí, 78200
Local Institution - 0095
Veracruz, 91900
China8 sites
Local Institution - 0159
Beijing, Beijing Municipality, 100005
Local Institution - 0190
Chongqing, Chongqing Municipality, 400010
Local Institution - 0150
Dalian, Liaoning, 116000
Local Institution - 0147
Guangzhou, Guangdong, 510120
Local Institution - 0149
Hefei, Anhui, 230071
Local Institution - 0146
Shanghai, Shanghai Municipality, 200040
Local Institution - 0143
Shenzhen, Guangdong, 518020
Local Institution - 0145
Yiwu, Zhejiang, 322000
Colombia8 sites
Local Institution - 0072
Barranquilla, 080020
Local Institution - 0069
Bogotá, 110221
Local Institution - 0063
Bogotá, 111156
Local Institution - 0071
Bucaramanga, Santander Department, 680003
Local Institution - 0070
Cali, 760042
Local Institution - 0094
Medellín, 050021
Local Institution - 0064
Medellín, 050034
Local Institution - 0065
Zipaquirá, 250252
Hungary8 sites
Local Institution - 0023
Budapest, 1027
Local Institution - 0142
Budapest, 1027
Local Institution - 0026
Budapest, 1033
Local Institution - 0025
Budapest, 1036
Local Institution - 0203
Budapest, 1036
Local Institution - 0270
Gyula, Bekes County, 5700
Local Institution - 0049
Székesfehérvár, Fejér, 8000
Local Institution - 0068
Zalaegerszeg, 8900
Brazil7 sites
Local Institution - 0219
Curitiba, Paraná, 80030110
Local Institution - 0214
Curitiba, Paraná, 80440-080
Local Institution - 0002
Juiz de Fora, Minas Gerais, 36010-570
Local Institution - 0005
Porto Alegre, Rio Grande do Sul, 90480-000
Local Institution - 0001
Salvador, Estado de Bahia, 40150-150
Local Institution - 0108
Santo André, São Paulo, 09060-870
Local Institution - 0109
Vitória, Espírito Santo, 29055450
Czechia7 sites
Local Institution - 0018
Ostrava, 722 00
Local Institution - 0208
Pardubice, 530 02
Local Institution - 0225
Prague, Praha 5, 150 06
Local Institution - 0097
Prague, 12850
Local Institution - 0017
Prague, 130 00
Local Institution - 0269
Uherské Hradiště, Zlín, 68601
Local Institution - 0202
Zlín, Zlín, 760 01
Australia6 sites
Local Institution - 0137
Botany, New South Wales, 2019
Local Institution - 0136
Camberwell, Victoria, 3142
Local Institution - 0211
Hobart, Tasmania, 7000
Local Institution - 0220
Phillip, Australian Capital Territory, 2606
Local Institution - 0133
Westmead, New South Wales, 2145
Local Institution - 0132
Woolloongabba, Queensland, 4102
Chile6 sites
Local Institution - 0226
Santiago, Santiago Metropolitan, 0
Local Institution - 0099
Santiago, Santiago Metropolitan, 7500571
Local Institution - 0073
Santiago, Santiago Metropolitan, 7501126
Local Institution - 0222
Santiago, Santiago Metropolitan, 7510047
Local Institution - 0111
Santiago, Santiago Metropolitan, 7640881
Local Institution - 0261
Viña del Mar, Valparaiso, 2531172
Taiwan5 sites
Local Institution - 0123
Kaohsiung City, 833401
Local Institution - 0121
Tainan, 704
Local Institution - 0122
Tainan, 710
Local Institution - 0120
Taipei, 110
Local Institution - 0124
Taoyuan, 333423
Ireland4 sites
Local Institution - 0101
Dublin, 4
Local Institution - 0102
Dublin, D15 X40D
Local Institution - 0103
Galway, H91 TY80
Local Institution - 0104
Manorhamilton, Leitrim, F91 X012
Italy4 sites
Local Institution - 0066
Genova, 16132
Local Institution - 0062
Pavia, 27100
Local Institution - 0096
Udine, 33100
Local Institution - 0058
Verona, 37134
Russia4 sites
Local Institution
Kemerovo, 650070
Local Institution
Korolyov, 141060
Local Institution
Saint Petersburg, 194214
Local Institution
Yaroslavl, 150003
Spain4 sites
Local Institution - 0021
A Coruña, 15006
Local Institution - 0022
Córdoba, 14004
Local Institution - 0019
Madrid, 28046
Local Institution - 0020
Sabadell, 08208
Finland3 sites
Local Institution - 0013
Helsinki, 00290
Local Institution - 0089
Kuopio, 70100
Local Institution - 0119
Turku, FI-20521
France3 sites
Local Institution - 0077
Chambray-lès-Tours, 37170
Local Institution - 0075
Montpellier, 34295
Local Institution - 0074
Paris, 75010
United Kingdom3 sites
Local Institution - 0116
Harlow, CM227NR
Local Institution - 0106
Southampton, Hampshire, SO16 6YD
Local Institution - 0107
Stoke-on-Trent, ST6 7AG
About this study
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.
- Conditions
- Psoriatic Arthritis
- Being tested
- Deucravacitinib, Placebo
- Keywords
- Biologic-Naive, BMS-986165, Deucravacitinib, Disease-modifying Anti-rheumatic Drugs, DMARDs, Joint Disease, Psoriatic Arthritis, PsA
- Medical subject headings
- Arthritis, Psoriatic, Joint Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DeucravacitinibDrug
Also called BMS-986165
Specified dose on specified days
PlaceboOther
Specified dose on specified days
| Study group | Role | What they receive |
|---|---|---|
| Deucravacitinib | Experimental | Not described Receives: Drug: Deucravacitinib |
| Placebo | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With ACR 20 Response at Week 16
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.
Measured: Week 16
Secondary outcomes (58)
Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: < 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; >5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.
Measured: Baseline and Week 16
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 16
HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.
Measured: Baseline and Week 16
Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response at Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.
Measured: Week 16
Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score at Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.
Measured: Baseline and Week 16
Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16
Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.
Measured: Week 16
Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16
Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16:
- Tender joint count <= 1
- Swollen joint count <=1
- Psoriasis Area and Severity Index (PASI) <= 1 or body surface area (BSA) <= 3%
- Patient assessment of psoriatic arthiritis (PsA) pain <= 15
- Patient Global Assessment of PsA disease activity <= 20
- HAQ-DI <= 0.5
- Tender enthesial points <= 1
Measured: Week 16
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16
FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.
Measured: Baseline and Week 16
Percentage of Participants Meeting Dactylitis Resolution at Week 16
Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count => 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.
Measured: Week 16
Change From Baseline in PsA-modified Sharp-van Der Heijde (SvdH) Score at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. Change from baseline reflects progression or improvement; a decrease suggests reduced damage or improvement.
Measured: Baseline and Week 16
Percentage of Participants With ACR 20 Response up to Week 16
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.
Measured: Week 2, 4, 8, 12, and 16
Percentage of Participants With ACR 50 Response up to Week 16
The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.
Measured: Week 2, 4, 8, 12, and 16
Percentage of Participants With ACR 70 Response up to Week 16
The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.
Measured: Week 2, 4, 8, 12, and 16
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16
HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.
Measured: Baseline and Week 2, 4, 8, 12, and 16
Percentage of Participants Who Achieve a Clinically Meaningful Improvement in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16 Among Participants With a HAQ-DI Score ≥0.35 at Baseline
HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Clinically meaningful improvement was defined as ≥0.35improvement from baseline.
Measured: Baseline and Week 2, 4, 8, 12, and 16
Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.
Measured: Week 4, 8, 12 and 16
Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 90 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.
Measured: Week 4, 8, 12 and 16
Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 100 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.
Measured: Week 4, 8, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.
Measured: Baseline and Week 4, 12 and 16
Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) up to Week 16
Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.
Measured: Week 4, 8, 12 and 16
Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Spondyloarthritis Research Consortium of Canada (SPARCC) up to Week 16
Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by SPARCC. The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (right \[R\]/left \[L\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.
Measured: Week 4, 8, 12 and 16
Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) up to Week 16
Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16:
- Tender joint count <= 1
- Swollen joint count <=1
- Psoriasis Area and Severity Index (PASI) <= 1 or body surface area (BSA) <= 3%
- Patient assessment of psoriatic arthiritis (PsA) pain <= 15
- Patient Global Assessment of PsA disease activity <= 20
- HAQ-DI <= 0.5
- Tender enthesial points <= 1
Measured: Week 4, 8, 12, and 16
Change From Baseline in the 36-item Short Form (SF-36) Mental Component Summary (MCS) Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The MCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 MCS indicates an improvement.
Measured: Baseline and Week 4, 12 and 16
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score up to Week 16
FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.
Measured: Baseline and Week 2, 4, 8, 12 and 16
Percentage of Participants Meeting Dactylitis Resolution up to Week 16
Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count => 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.
Measured: Week 4, 8, 12 and 16
Change From Baseline in Psoriatic Arthritis Impact of Disease (PsAID) 12 Score up to Week 16
The Psoriatic Arthritis Impact of Disease (PsAID) is a 12-item self-report that measures PsA symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale with a 1-week recall period. The PsAID has a total score, with a higher value indicating worse health. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in PsAID indicates an improvement.
Measured: Baseline and Week 2, 4, 8, 12 and 16
Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score up to Week 16
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. The DAPSA score ranges from 0 to 154, with a higher score indicating more disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAPSA indicates an improvement.
Measured: Baseline and Week 2, 4, 8, 12 and 16
Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Low Disease Activity Response up to Week 16
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.
Measured: Baseline and Week 2, 4, 8, 12 and 16
Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Disease Remission up to Week 16
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity. A score 0 signifies remission.
Measured: Baseline and Week 2, 4, 8, 12 and 16
Percentage of Participants Meeting Achievement of Physician Global Assessment-Fingernails (PGA-F) of 0/1 up to Week 16
The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe. The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe.
Measured: Week 2, 4, 8, 12 and 16
Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) up to Week 16
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.
Measured: Baseline and Week 2, 4, 8, 12 and 16
Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Low Disease Activity Response up to Week 16
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity.
Measured: Week 2, 4, 8, 12 and 16
Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Disease Remission up to Week 16
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity.
Measured: Week 2, 4, 8, 12 and 16
Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) up to Week 16
The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite measure calculated from the Physician Global Assessment of PsA, the Participant Global Assessment of Disease Activity, the Short Form-36 PCS, the swollen joint count, the tender joint count, the Enthesitis (LEI), the Dactylitis (LDI) (Basic), and the High-sensitivity C-reactive protein (hsCRP). The range of PASDAS is 0-10. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Measured: Baseline and Week 4, 12 and 16
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) up to Week 16
Four domains are used to calculate the modified Composite Psoriatic Disease Activity Index (mCPDAI): joints (66 swollen joint count and 68 tender joint count; Health Assessment Questionnaire), skin (PASI and DLQI), dactylitis (a simple count of each digit involved), and enthesitis (number of tendons/fascia insertion sites showing enthesitis scored from 0 to 4, based on palpation of Achilles tendon and bilateral plantar fasciae insertion). The mCPDAI is scored using a 4 point scale from 0 (no disease activity) to 3 (most severe disease activity), giving an mCPDAI score range of 0 through 12. A higher score indicates more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Measured: Baseline and Week 4, 8, 12 and 16
Percentage of Participants With Achievement of Psoriatic Arthritis Response Criteria (PsARC) up to Week 16
The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender joint count, swollen joint count, Physician Global Assessment of PsA, and Participant Global Assessment of Disease Activity. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement in each of the measures is defined below: 1) Decrease of ≥ 30% in tender joint counts; 2) Decrease of ≥ 30% in swollen joint counts; 3) Decrease of ≥ 20% in Physician Global Assessment of PsA; 4) Decrease of ≥ 20% in Participant's Global Assessment of Disease Activity
Measured: Week 2, 4, 8, 12 and 16
Percentage of Participants Meeting Achievement of Improvement of Bath Ankylosing Spondylitis Disease Activity (BASDAI) Score up to Week 16
BASDAI consists of a 0 to 10 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: 1) Fatigue (medical); 2) Spinal pain; 3) Joint pain and swelling; 4) Areas of localized tenderness; 5) Morning stiffness duration; 6) Morning stiffness severity. A higher count indicates worse disease. Each individual question response is scaled to a 0-10 score by dividing by 10, and the BASDAI is derived using the following formula: BASDAI = ((Q1 + Q2 + Q3 + Q4) + ((Q5 + Q6) / 2)) / 5
Measured: Week 2, 4, 8, 12 and 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0 at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Measured: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0.5 at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Measured: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= Smallest Detectable Change (SDC) at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96* standard deviation of the paired differences of change from baseline/ square root of (2*k); k is the number of reviewers and is default to 2 in this study.
Measured: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0 at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Measured: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0.5 at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Measured: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= SDC at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96* standard deviation of the paired differences of change from baseline/ square root of (2*k); k is the number of reviewers and is default to 2 in this study.
Measured: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0 at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Measured: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0.5 at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Measured: Week 16
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= SDC at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96* standard deviation of the paired differences of change from baseline/ square root of (2*k); k is the number of reviewers and is default to 2 in this study.
Measured: Week 16
Change From Baseline in PsA-modified SvdH Erosion Scores Response at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Measured: Baseline and Week 16
Change From Baseline in PsA-modified SvdH JSN Scores Response at Week 16
The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.
Measured: Baseline and Week 16
Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical sub component is one of the 4 subscales of PCS. The physical subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 physical sub-component indicates an improvement.
Measured: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Role Activity Subcomponent Summary Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The role activity sub component is one of the 4 subscales of PCS. The role activity subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 role activity indicates an improvement.
Measured: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Bodily Pain Subcomponent Summary Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The bodily pain sub component is one of the 4 subscales of PCS. The bodily pain subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 bodily pain subcomponent indicates an improvement.
Measured: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) General Health Perceptions Subcomponent Summary Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The general health perceptions sub component is one of the 4 subscales of PCS. The general health perceptions subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 general health perceptions subcomponent indicates an improvement.
Measured: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Vitality Subcomponent Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The vitality subcomponent is one of the 4 subscales of MCS. The vitality subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 vitality subcomponent indicates an improvement.
Measured: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Social Subcomponent Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The social subcomponent is one of the 4 subscales of MCS. The social subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 social subcomponent indicates an improvement.
Measured: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Mental Health Subcomponent Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental health subcomponent is one of the 4 subscales of MCS. The mental health subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 mental health subcomponent indicates an improvement.
Measured: Baseline and Week 4, 12 and 16
Change From Baseline in the 36-item Short Form (SF-36) Emotional Problems Subcomponent Score up to Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The emotional problem subcomponent is one of the 4 subscales of MCS. The emotional problem subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 emotional problems subcomponent indicates an improvement.
Measured: Baseline and Week 4, 12 and 16
Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Subcomponents Score at Week 16
WPAI contains 4 subcomponents - absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity (overall work impairment/absenteeism plus presenteeism), and activity impairment. Each subcomponent score ranges from 0 to 100, with higher numbers indicating worse outcome. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Measured: Baseline and week 16
Change From Baseline in the European Quality of Life 5D-5L (EQ-5D-5L) Utility Scores and Its Subcomponents up to 16
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. Change from Baseline in 5-level EuroQol 5-dimension (EQ-5D-5L) Utility Scores. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Measured: Baseline and week 4 and 16
Change From Baseline in Patient-Reported Outcome Measures Information System (PROMIS) Sleep Disturbance up to Week 16
The Patient-Reported Outcome Measures Information System Sleep Disturbance assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. The items are evaluated on a 5-point Likert scale ranging from 1 = "not at all" to 5 = "very much" with a 7-day recall period. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Measured: Baseline and week 4, 12, and 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jun 2021
- Study start13 Jul 2021
- Primary completion10 Oct 2024
- Study completion3 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Psoriatic ArthritisStudies of the same condition, open and under way.
- More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 670 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bristol-Myers Squibb, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04908202
- Sponsor's protocol ID
- IM011-054
- Other IDs
- 2023-506256-25, U1111-1259-9443, 2023
- Status last verified
- Sep 2026
- First submitted
- 28 May 2021
- Last updated
- 16 Oct 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html